UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high‐dose chemoradiotherapy for patients with malignancyKenneth Douglas, Keith Wilson, Maria Gilleece et al.|Journal of Clinical Apheresis|2017Cited by 50
Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR T cell therapy, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL.Wendy Osborne, Kirit M. Ardeshna, Maria A. V. Marzolini et al.|Journal of Clinical Oncology|2020Cited by 45
Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)Enrico Maffini, Mohamad Mohty, Maud Ngoya et al.|Bone Marrow Transplantation|2023Cited by 19
890MO Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR.T cell, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCLEleni Tholouli, K. Ardesha, Wendy Osborne et al.|Annals of Oncology|2020Cited by 4
A Noninterventional, Observational, European Post-Authorization Safety Study of Patients With Relapsed/Refractory Multiple Myeloma Treated With LenalidomideBarbara Gamberi, Igor Wolfgang Blau, Christian Berthou et al.|Clinical Lymphoma Myeloma & Leukemia|2020Cited by 2